| Year |
Citation |
Score |
| 2022 |
Koubek EJ, Weissenrieder JS, Ortiz LE, Nwogu N, Pham AM, Weissenkampen JD, Reed JL, Neighbors JD, Hohl RJ, Kwun HJ. Therapeutic Potential of 5'-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma. Viruses. 14. PMID 36146655 DOI: 10.3390/v14091848 |
0.303 |
|
| 2019 |
Larson-Casey JL, Vaid M, Gu L, He C, Cai GQ, Ding Q, Davis D, Berryhill TF, Wilson LS, Barnes S, Neighbors JD, Hohl RJ, Zimmerman KA, Yoder BK, Longhini ALF, et al. Increased flux through the mevalonate pathway mediates fibrotic repair without injury. The Journal of Clinical Investigation. PMID 31609245 DOI: 10.1172/Jci127959 |
0.302 |
|
| 2019 |
Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614 |
0.316 |
|
| 2018 |
Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ. Schweinfurthins: Lipid Modulators with Promising Anticancer Activity. Lipids. PMID 30334267 DOI: 10.1002/Lipd.12088 |
0.408 |
|
| 2018 |
Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Khawaja MR, Sivik J, Han J, Hohl RJ, Zheng H. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology. 7: e1469594. PMID 30228937 DOI: 10.1080/2162402X.2018.1469594 |
0.353 |
|
| 2018 |
Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. The Prostate. PMID 30106164 DOI: 10.1002/Pros.23707 |
0.688 |
|
| 2018 |
Jia B, Zhao C, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Khawaja M, Hohl RJ, Zheng H. TIGIT Expression Positively Associates with NK Cell Function in AML Patients Blood. 132: 5250-5250. DOI: 10.1182/Blood-2018-99-113578 |
0.328 |
|
| 2017 |
Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 10: 124. PMID 28629373 DOI: 10.1186/S13045-017-0486-Z |
0.304 |
|
| 2017 |
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, ... ... Hohl RJ, et al. O2(⋅-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. PMID 28366679 DOI: 10.1016/J.Ccell.2017.02.018 |
0.348 |
|
| 2016 |
Reilly JE, Neighbors JD, Hohl RJ. Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biology & Therapy. 0. PMID 27624889 DOI: 10.1080/15384047.2016.1219817 |
0.697 |
|
| 2015 |
Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines. Lipids. PMID 26494560 DOI: 10.1007/S11745-015-4083-Z |
0.779 |
|
| 2015 |
Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clinical & Experimental Metastasis. 32: 555-66. PMID 26070429 DOI: 10.1007/S10585-015-9727-0 |
0.694 |
|
| 2015 |
Sheehy RM, Kuder CH, Bachman Z, Hohl RJ. Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil. Cancer Biology & Therapy. 16: 1259-68. PMID 26046259 DOI: 10.1080/15384047.2015.1056420 |
0.77 |
|
| 2015 |
Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors. Biochemical Pharmacology. 96: 83-92. PMID 25952057 DOI: 10.1016/J.Bcp.2015.04.009 |
0.789 |
|
| 2014 |
Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF. Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein Journal of Organic Chemistry. 10: 1645-50. PMID 25161722 DOI: 10.3762/Bjoc.10.171 |
0.692 |
|
| 2014 |
Sheehy RM, Bachman ZC, Hohl RJ. Abstract 811: Schweinfurthin activity enhanced by verapamil Cancer Research. 74: 811-811. DOI: 10.1158/1538-7445.Am2014-811 |
0.401 |
|
| 2014 |
Reilly JE, Neighbors JD, Bannick N, Henry MD, Kuder CH, Hohl RJ. Abstract 4032: Targeting the isoprenoid biosynthetic pathway in a murine model of metastatic prostate cancer Cancer Research. 74: 4032-4032. DOI: 10.1158/1538-7445.Am2014-4032 |
0.769 |
|
| 2013 |
Tong H, Kuder CH, Wasko BM, Hohl RJ. Quantitative determination of isopentenyl diphosphate in cultured mammalian cells. Analytical Biochemistry. 433: 36-42. PMID 23000003 DOI: 10.1016/J.Ab.2012.09.001 |
0.771 |
|
| 2013 |
Bhasin N, Stevens J, Niki M, Tong H, Kuder C, Hohl RJ, Lentz SR. Dissecting The Effects Of Isoprenoid Pathway Inhibition On Hemostasis and Thrombosis: Differential Effects Of Atorvastatin and Digeranyl Bisphosphonate In Hypercholesterolemic Mice Blood. 122: 2378-2378. DOI: 10.1182/Blood.V122.21.2378.2378 |
0.739 |
|
| 2012 |
Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Current Opinion in Pharmacology. 12: 704-9. PMID 22817869 DOI: 10.1016/J.Coph.2012.06.013 |
0.325 |
|
| 2012 |
Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ. Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification. Molecular Pharmacology. 82: 9-16. PMID 22461663 DOI: 10.1124/Mol.111.077107 |
0.792 |
|
| 2012 |
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, ... ... Hohl R, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.Capr-11-0455 |
0.327 |
|
| 2012 |
Weivoda MM, Hohl RJ. Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation. Bone. 50: 467-76. PMID 22019459 DOI: 10.1016/J.Bone.2011.09.056 |
0.721 |
|
| 2011 |
Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clinical Pharmacology and Therapeutics. 90: 804-12. PMID 22048229 DOI: 10.1038/Clpt.2011.215 |
0.647 |
|
| 2011 |
Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro. Journal of Lipid Research. 52: 1957-64. PMID 21903868 DOI: 10.1194/Jlr.M016089 |
0.443 |
|
| 2011 |
Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, ... ... Hohl R, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 118: 4882-9. PMID 21725056 DOI: 10.1182/Blood-2011-02-334904 |
0.312 |
|
| 2011 |
Holstein SA, Kuder CH, Tong H, Hohl RJ. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids. 46: 907-21. PMID 21633866 DOI: 10.1007/S11745-011-3572-Y |
0.794 |
|
| 2011 |
Weivoda MM, Hohl RJ. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology. 152: 3113-22. PMID 21586555 DOI: 10.1210/En.2011-0016 |
0.727 |
|
| 2011 |
Weivoda MM, Hohl RJ. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. Journal of Cellular Biochemistry. 112: 1506-13. PMID 21503955 DOI: 10.1002/Jcb.23087 |
0.723 |
|
| 2011 |
Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. The Journal of Pharmacology and Experimental Therapeutics. 337: 540-6. PMID 21335425 DOI: 10.1124/Jpet.110.175521 |
0.66 |
|
| 2011 |
Holstein SA, Hohl RJ. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Research. 35: 551-9. PMID 20828814 DOI: 10.1016/J.Leukres.2010.08.008 |
0.424 |
|
| 2011 |
Dandamudi UB, Adams LM, Johnson B, Bauman J, Morris S, Murray S, Webb RT, Gartner E, Hohl R, Lewis LD. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer Cancer Chemotherapy and Pharmacology. 67: 783-790. PMID 20556613 DOI: 10.1007/S00280-010-1381-2 |
0.326 |
|
| 2011 |
Dudakovic A, Tong H, Hohl RJ. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Investigational New Drugs. 29: 912-20. PMID 20480384 DOI: 10.1007/S10637-010-9446-Y |
0.684 |
|
| 2011 |
Holstein SA, Hohl RJ. Inhibition of Farnesyl and Geranylgeranyl Diphosphate Synthases Enzymes. 30: 301-319. DOI: 10.1016/B978-0-12-415922-8.00013-6 |
0.391 |
|
| 2010 |
Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF. Biologically active biotin derivatives of schweinfurthin F. Bioorganic & Medicinal Chemistry Letters. 20: 6716-20. PMID 20869871 DOI: 10.1016/J.Bmcl.2010.08.143 |
0.762 |
|
| 2010 |
Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorganic & Medicinal Chemistry. 18: 7212-20. PMID 20832326 DOI: 10.1016/J.Bmc.2010.08.036 |
0.66 |
|
| 2010 |
Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Fluorescent schweinfurthin B and F analogs with anti-proliferative activity. Bioorganic & Medicinal Chemistry. 18: 6734-41. PMID 20724169 DOI: 10.1016/J.Bmc.2010.07.056 |
0.779 |
|
| 2010 |
Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorganic & Medicinal Chemistry. 18: 1676-83. PMID 20116262 DOI: 10.1016/J.Bmc.2009.12.063 |
0.773 |
|
| 2010 |
Holstein SA, Tong H, Hohl RJ. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Research. 34: 344-51. PMID 19646757 DOI: 10.1016/J.Leukres.2009.06.035 |
0.431 |
|
| 2010 |
Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Weiner G, ... Hohl RJ, et al. A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas Blood. 116: 287-287. DOI: 10.1182/Blood.V116.21.287.287 |
0.319 |
|
| 2009 |
Holstein SA, Tong H, Kuder CH, Hohl RJ. Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 44: 1055-62. PMID 19856009 DOI: 10.1007/S11745-009-3355-X |
0.791 |
|
| 2009 |
Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anti-Cancer Agents in Medicinal Chemistry. 9: 526-42. PMID 19519294 DOI: 10.2174/187152009788451860 |
0.712 |
|
| 2009 |
Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Synthesis and biological activity of a fluorescent schweinfurthin analogue. Bioorganic & Medicinal Chemistry. 17: 4718-23. PMID 19464190 DOI: 10.1016/J.Bmc.2009.04.071 |
0.78 |
|
| 2009 |
Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia & Lymphoma. 50: 559-65. PMID 19373653 DOI: 10.1080/10428190902748971 |
0.302 |
|
| 2008 |
Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Analytical Biochemistry. 378: 138-43. PMID 18457649 DOI: 10.1016/J.Ab.2008.04.021 |
0.63 |
|
| 2008 |
Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorganic & Medicinal Chemistry. 16: 3652-60. PMID 18308574 DOI: 10.1016/J.Bmc.2008.02.016 |
0.715 |
|
| 2008 |
Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. The Journal of Pharmacology and Experimental Therapeutics. 324: 1028-36. PMID 18083912 DOI: 10.1124/Jpet.107.132217 |
0.781 |
|
| 2008 |
Hamadmad SN, Hohl RJ. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. The Journal of Pharmacology and Experimental Therapeutics. 324: 1227-33. PMID 18079357 DOI: 10.1124/Jpet.107.129643 |
0.799 |
|
| 2008 |
Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic & Medicinal Chemistry. 16: 390-9. PMID 17905588 DOI: 10.1016/J.Bmc.2007.09.029 |
0.708 |
|
| 2008 |
Holstein SA, Tong H, Hohl RJ. Biochemical Basis for Interactions Between Thalidomide and Inhibitors of the Isoprenoid Biosynthetic Pathway in Multiple Myeloma Cells Blood. 112: 2635-2635. DOI: 10.1182/Blood.V112.11.2635.2635 |
0.455 |
|
| 2007 |
Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochemical Pharmacology. 74: 590-600. PMID 17586475 DOI: 10.1016/J.Bcp.2007.04.028 |
0.802 |
|
| 2007 |
Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorganic & Medicinal Chemistry. 15: 1959-66. PMID 17254791 DOI: 10.1016/J.Bmc.2007.01.002 |
0.787 |
|
| 2007 |
Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Bioorganic & Medicinal Chemistry Letters. 17: 911-5. PMID 17236766 DOI: 10.1016/J.Bmcl.2006.11.096 |
0.596 |
|
| 2007 |
Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochemical and Biophysical Research Communications. 353: 921-5. PMID 17208200 DOI: 10.1016/J.Bbrc.2006.12.094 |
0.706 |
|
| 2006 |
Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorganic & Medicinal Chemistry. 14: 4130-6. PMID 16517172 DOI: 10.1016/J.Bmc.2006.02.010 |
0.691 |
|
| 2006 |
Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Current Cancer Drug Targets. 6: 15-37. PMID 16475974 DOI: 10.2174/156800906775471743 |
0.421 |
|
| 2006 |
Hamadmad SN, Henry MK, Hohl RJ. Erythropoietin receptor signal transduction requires protein geranylgeranylation. The Journal of Pharmacology and Experimental Therapeutics. 316: 403-9. PMID 16203826 DOI: 10.1124/Jpet.105.092510 |
0.789 |
|
| 2006 |
Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology. 57: 155-64. PMID 16133537 DOI: 10.1007/S00280-005-0013-8 |
0.313 |
|
| 2006 |
Askeland EJ, Wiemer AJ, Hohl RJ. Synergism between Anti-Leukemia Therapeutics and Isoprenoid Pathway Inhibitors in K562 Leukemia Cells. Blood. 108: 4815-4815. DOI: 10.1182/Blood.V108.11.4815.4815 |
0.71 |
|
| 2005 |
Murthy S, Tong H, Hohl RJ. Regulation of fatty acid synthesis by farnesyl pyrophosphate. The Journal of Biological Chemistry. 280: 41793-804. PMID 16221687 DOI: 10.1074/Jbc.M504101200 |
0.354 |
|
| 2005 |
Lewis KA, Holstein SA, Hohl RJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leukemia Research. 29: 527-33. PMID 15755505 DOI: 10.1016/J.Leukres.2004.10.007 |
0.371 |
|
| 2005 |
Tong H, Holstein SA, Hohl RJ. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Analytical Biochemistry. 336: 51-9. PMID 15582558 DOI: 10.1016/J.Ab.2004.09.024 |
0.372 |
|
| 2005 |
Swanson KM, Tong H, Wiemer AJ, Murthy S, Hohl RJ. Potential mechanisms for the anti-myeloma properties of bisphosphonates Journal of Clinical Oncology. 23: 6586-6586. DOI: 10.1200/Jco.2005.23.16_Suppl.6586 |
0.705 |
|
| 2004 |
Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues. The Journal of Organic Chemistry. 69: 8186-93. PMID 15549786 DOI: 10.1021/Jo049101W |
0.681 |
|
| 2004 |
Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids. 39: 293-309. PMID 15357017 DOI: 10.1007/S11745-004-1233-3 |
0.324 |
|
| 2004 |
Henry MK, Nimbalkar D, Hohl RJ, Quelle FW. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Experimental Cell Research. 299: 257-66. PMID 15302592 DOI: 10.1016/J.Yexcr.2004.06.003 |
0.397 |
|
| 2004 |
Swanson KM, Wiemer AJ, Hohl RJ. Bisphosphonates Influence Isoprenylation of Small Gtpases in Human Myeloma Cells. Blood. 104: 3401-3401. DOI: 10.1182/Blood.V104.11.3401.3401 |
0.706 |
|
| 2004 |
Sbaity SA, Murthy S, Romig S, Hohl R, Weintraub N, Stoll L. 1122-169 Statins block endotoxin-induced proinflammatory responses in human coronary artery cells by inhibition of Rho protein-mediated signaling Journal of the American College of Cardiology. 43: A498. DOI: 10.1016/S0735-1097(04)92108-0 |
0.323 |
|
| 2003 |
Ownby SE, Hohl RJ. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids. 38: 751-9. PMID 14506838 DOI: 10.1007/S11745-003-1123-8 |
0.781 |
|
| 2003 |
Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry. 42: 4384-91. PMID 12693933 DOI: 10.1021/Bi027227M |
0.359 |
|
| 2003 |
Holstein SA, Hohl RJ. Monoterpene regulation of Ras and Ras-related protein expression. Journal of Lipid Research. 44: 1209-15. PMID 12671036 DOI: 10.1194/Jlr.M300057-Jlr200 |
0.349 |
|
| 2002 |
Chen X, Wiemer AJ, Hohl RJ, Wiemer DF. Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside. The Journal of Organic Chemistry. 67: 9331-9. PMID 12492335 DOI: 10.1021/Jo020483K |
0.649 |
|
| 2002 |
Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry. 41: 13698-704. PMID 12427032 DOI: 10.1021/Bi026251X |
0.322 |
|
| 2002 |
Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 37: 185-92. PMID 11908910 DOI: 10.1007/S11745-002-0879-1 |
0.789 |
|
| 2002 |
Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. The Journal of Biological Chemistry. 277: 10678-82. PMID 11788600 DOI: 10.1074/Jbc.M111369200 |
0.32 |
|
| 2002 |
Chen X, Jung KY, Wiemer DF, Wiemer AJ, Hohl RJ. Phosphonate analogues of cytosine arabinoside monophosphate Phosphorus, Sulfur and Silicon and Related Elements. 177: 1783-1786. DOI: 10.1080/10426500212248 |
0.656 |
|
| 2001 |
Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells Molecular Cancer Therapeutics. 1: 141-149. PMID 12467231 |
0.316 |
|
| 2001 |
Holstein SA, Hohl RJ. Interaction of cytosine arabinoside and lovastatin in human leukemia cells Leukemia Research. 25: 651-660. PMID 11397469 DOI: 10.1016/S0145-2126(00)00162-4 |
0.354 |
|
| 2000 |
Cermak DM, Wiemer DF, Lewis K, Hohl RJ. 2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization Bioorganic and Medicinal Chemistry. 8: 2729-2737. PMID 11131164 DOI: 10.1016/S0968-0896(00)00212-1 |
0.377 |
|
| 2000 |
Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorganic & Medicinal Chemistry. 8: 2501-9. PMID 11058045 DOI: 10.1016/S0968-0896(00)00183-8 |
0.658 |
|
| 1998 |
Holstein SA, Cermak DM, Wiemer DF, Lewis K, Hohl RJ. Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase Bioorganic and Medicinal Chemistry. 6: 687-694. PMID 9681134 DOI: 10.1016/S0968-0896(98)00034-0 |
0.363 |
|
| 1998 |
Hohl RJ, Lewis KA, Cermak DM, Wiemer DF. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids Lipids. 33: 39-46. PMID 9470172 DOI: 10.1007/S11745-998-0178-X |
0.346 |
|
| 1996 |
Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras Blood. 88: 4611-4619. PMID 8977253 DOI: 10.1182/Blood.V88.12.4611.Bloodjournal88124611 |
0.382 |
|
| 1996 |
Hohl RJ. Monoterpenes as regulators of malignant cell proliferation Advances in Experimental Medicine and Biology. 401: 137-146. PMID 8886132 DOI: 10.1007/978-1-4613-0399-2_11 |
0.344 |
|
| 1995 |
Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing Journal of Biological Chemistry. 270: 17508-17512. PMID 7615555 DOI: 10.1074/Jbc.270.29.17508 |
0.325 |
|
| 1991 |
Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells Blood. 77: 1064-1070. PMID 1995091 DOI: 10.1182/Blood.V77.5.1064.Bloodjournal7751064 |
0.358 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2018 |
Zhao C, Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Khawaja M, Hohl RJ, Zheng H. Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML Blood. 132: 1526-1526. DOI: 10.1182/Blood-2018-99-113547 |
0.299 |
|
| 2012 |
Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011 Clinical Pharmacology and Therapeutics. 91: 15-17. PMID 22179625 DOI: 10.1038/Clpt.2011.288 |
0.299 |
|
| 1997 |
Lewis KA, Hohl RJ. Modulation of RAS expression in human malignant cells by dietary supplements Nutrition. 13: 921-923. PMID 9357036 DOI: 10.1016/S0899-9007(97)00261-X |
0.297 |
|
| 2016 |
Raje N, Faber E, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser C, Cronier DM, Wooldridge JE, Anderson KC. Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27287072 DOI: 10.1158/1078-0432.Ccr-16-0201 |
0.297 |
|
| 2019 |
Weissenrieder JS, Reed JL, Green MV, Moldovan GL, Koubek EJ, Neighbors JD, Hohl RJ. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells. Pharmacology. 1-9. PMID 31645049 DOI: 10.1159/000502562 |
0.295 |
|
| 2016 |
Pu JJ, Ehmann WC, Liao J, Capper C, Levy M, Claxton DF, Rybka WB, Hohl RJ, Epner EM. The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma Blood. 128: 1792-1792. DOI: 10.1182/Blood.V128.22.1792.1792 |
0.295 |
|
| 2017 |
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, ... ... Hohl RJ, et al. O2(⋅-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 32: 268. PMID 28810149 DOI: 10.1016/J.Ccell.2017.07.008 |
0.294 |
|
| 2004 |
Hohl R. Statins decrease levels of the estrogen receptor in human breast cancers Clinical Pharmacology & Therapeutics. 75: P45. DOI: 10.1016/J.Clpt.2003.11.170 |
0.291 |
|
| 2006 |
Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg S, Bhushan V, Shammo J, Hohl R, Li Y, Lowe A, Zhu J, List A. Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS). Blood. 108: 2657-2657. DOI: 10.1182/Blood.V108.11.2657.2657 |
0.291 |
|
| 2007 |
Xing D, Murry DJ, Schmidt MS, Hohl RJ, Martins JB. Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm : the Official Journal of the Heart Rhythm Society. 4: 629-37. PMID 17467633 DOI: 10.1016/J.Hrthm.2006.12.051 |
0.291 |
|
| 2011 |
Raje NS, Hohl RJ, Faber EA, Richardson PG, Forero-Torres A, Schiller GJ, Cohen AD, Carpenter SP, Cronier D, Pashkevich M, Wooldridge J, Anderson KC. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8012. PMID 28022991 DOI: 10.1200/Jco.2011.29.15_Suppl.8012 |
0.291 |
|
| 2004 |
Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Smith S, Frankel S. Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM). Blood. 104: 1477-1477. DOI: 10.1182/Blood.V104.11.1477.1477 |
0.291 |
|
| 2019 |
Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ. Cancer and the dopamine D2 receptor: a pharmacological perspective. The Journal of Pharmacology and Experimental Therapeutics. PMID 31000578 DOI: 10.1124/Jpet.119.256818 |
0.29 |
|
| 2017 |
Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H. Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients Blood. 130: 3946-3946. DOI: 10.1182/Blood.V130.Suppl_1.3946.3946 |
0.288 |
|
| 2005 |
Magalhaes-Silverman M, Carter T, Gingrich R, Hohl R, Schlueter A. In vivo T cell depleted unrelated allogeneic stem cell transplantation with a reduced intensity regimen in patients with advanced hematologic malignancies Biology of Blood and Marrow Transplantation. 11: 22-23. DOI: 10.1016/J.Bbmt.2004.12.065 |
0.287 |
|
| 1996 |
Hohl R, Pogatchnik DM, Lewis-Tibesar K, Wiemer D. Inhibition of RAS farnesylation by isoprenoid phosphonic acids. Clinical Pharmacology & Therapeutics. 59: 198-198. DOI: 10.1038/Sj.Clpt.1996.290 |
0.285 |
|
| 2019 |
Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H. Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia (AML). Cancer Research. PMID 30709927 DOI: 10.1158/0008-5472.Can-18-3107 |
0.284 |
|
| 2015 |
Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Investigational New Drugs. 33: 594-602. PMID 25698442 DOI: 10.1007/S10637-015-0220-Z |
0.283 |
|
| 2017 |
Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabik JJ, Wang HG, Abraham T, ... ... Hohl RJ, et al. PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget. PMID 28187452 DOI: 10.18632/Oncotarget.15136 |
0.282 |
|
| 2003 |
Magalhaes-Silverman M, Lee C, Hohl R, Ritchie J, Gingrich R. 71 T-cell depleted allogeneic bone marrow transplantation followed by T cell add-back in patients with multiple myeloma Biology of Blood and Marrow Transplantation. 9: 86. DOI: 10.1016/S1083-8791(03)80072-1 |
0.276 |
|
| 1995 |
Clamon GH, Riggs CE, Dreicer R, Hohl RJ. Phase II trial of edatrexate in patients with metastatic colorectal cancer Investigational New Drugs. 13: 359-361. PMID 8824357 DOI: 10.1007/Bf00873145 |
0.276 |
|
| 2006 |
Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl R, Seagren SL, Bajorin DF, Small EJ. CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC) Journal of Clinical Oncology. 24: 4582-4582. DOI: 10.1200/Jco.2006.24.18_Suppl.4582 |
0.276 |
|
| 2008 |
Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 Annals of Oncology. 19: 946-950. PMID 18272914 DOI: 10.1093/Annonc/Mdm600 |
0.275 |
|
| 1998 |
Gao F, Hohl RJ, Shires TK. Geranylgeraniol restores cell growth and Ras processing in mevalonate-depleted fibroblast cells Faseb Journal. 12. |
0.274 |
|
| 2013 |
Xia C, Deutsch JM, Milhem MM, Smith BJ, Laux D, Hohl R. Abstract 2414: A phase I/II clinical trial to evaluate the efficacy of combined epigenetic therapy for improving temozolomide chemosensitivity in metastatic melanoma. Cancer Research. 73: 2414-2414. DOI: 10.1158/1538-7445.Am2013-2414 |
0.274 |
|
| 2012 |
Raje N, Faber EA, Richardson PG, Schiller GJ, Hohl RJ, Cohen AD, Forero A, Carpenter SP, Cronier D, Kaiser C, Wooldridge JE, Anderson KC. Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma Blood. 120: 447-447. DOI: 10.1182/Blood.V120.21.447.447 |
0.272 |
|
| 2003 |
Hohl RJ, Holstein SA, Wohlford-Lenane CL. Mevalonate depletion induces up-regulation of RAS and RAS-related proteins Clinical Pharmacology & Therapeutics. 73: P67-P67. DOI: 10.1016/S0009-9236(03)90606-0 |
0.272 |
|
| 2005 |
Stroh A, Carter TH, Hohl RJ, Zehr P, Ritchie JM. Pilot Study of Lovastatin in Patients with Myelodysplastic Syndrome (MDS) Receiving Arsenic Trioxide (Trisenox®) Therapy. Blood. 106: 4928-4928. DOI: 10.1182/Blood.V106.11.4928.4928 |
0.27 |
|
| 2009 |
Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leukemia Research. 33: 344-7. PMID 18835038 DOI: 10.1016/J.Leukres.2008.07.029 |
0.269 |
|
| 2002 |
Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma Bone Marrow Transplantation. 29: 615-620. PMID 11979313 DOI: 10.1038/Sj.Bmt.1703426 |
0.268 |
|
| 1999 |
Gingrich RD, Lee C, Hohl R, Joyce J, Burns LJ, Tamaki K, Wen B, Scott S. A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: A phase II study Biology of Blood and Marrow Transplantation. 5: 86-93. PMID 10371360 DOI: 10.1053/Bbmt.1999.V5.Pm10371360 |
0.267 |
|
| 2001 |
Kumar V, Kang J, Hohl RJ. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying Pharmaceutical Development and Technology. 6: 459-467. PMID 11485187 DOI: 10.1081/Pdt-100002254 |
0.267 |
|
| 2004 |
Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemotherapy and Pharmacology. 54: 368-76. PMID 15205914 DOI: 10.1007/S00280-004-0788-Z |
0.265 |
|
| 2012 |
Xia C, Laux DE, Deutsch JM, Frees M, Smith B, Hohl RJ, Milhem MM. A phase I/II study to evaluate the ability of decitabine and panobinostat to improve temozolomide chemosensitivity in metastatic melanoma. Journal of Clinical Oncology. 30: 3056-3056. DOI: 10.1200/Jco.2012.30.15_Suppl.3056 |
0.264 |
|
| 2018 |
Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer Journal. 8: 34. PMID 29563517 DOI: 10.1038/S41408-018-0069-4 |
0.263 |
|
| 2019 |
Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H. Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. British Journal of Haematology. PMID 31573077 DOI: 10.1111/Bjh.16228 |
0.261 |
|
| 2013 |
Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, et al. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 27: 977-80. PMID 23032694 DOI: 10.1038/Leu.2012.264 |
0.258 |
|
| 2022 |
Weissenrieder JS, Weissenkampen JD, Reed JL, Green MV, Zheng C, Neighbors JD, Liu DJ, Hohl RJ. RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins. Scientific Reports. 12: 359. PMID 35013404 DOI: 10.1038/s41598-021-04117-7 |
0.258 |
|
| 2003 |
Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep Journal of Pharmacology and Experimental Therapeutics. 306: 532-537. PMID 12750427 DOI: 10.1124/Jpet.103.052431 |
0.258 |
|
| 2007 |
Schlueter AJ, Glasgow JK, Wilke W, Marietta JR, Hohl RJ, Carter TH, Gingrich RD, Magalhaes-Silverman MD. Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma. Blood. 110: 951-951. DOI: 10.1182/Blood.V110.11.951.951 |
0.257 |
|
| 2000 |
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565 Journal of Clinical Oncology. 18: 2780-2787. PMID 10894879 DOI: 10.1200/Jco.2000.18.14.2780 |
0.257 |
|
| 2001 |
Hohl RJ, Holstein SA. Synergy of cytosine arabinoside and lovastatin in human leukemia cells Clinical Pharmacology and Therapeutics. 69. |
0.256 |
|
| 2015 |
Osborn-Heaford HL, Murthy S, Gu L, Larson-Casey JL, Ryan AJ, Shi L, Glogauer M, Neighbors JD, Hohl R, Brent Carter A. Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis. Free Radical Biology & Medicine. 86: 47-56. PMID 25958207 DOI: 10.1016/J.Freeradbiomed.2015.04.031 |
0.255 |
|
| 2007 |
Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Erratum: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies (Cancer Chemotherapy and Pharmacology 57, (155-164) DOI: 10.1007/s00280-005-0013-8) Cancer Chemotherapy and Pharmacology. 59. DOI: 10.1007/S00280-006-0330-6 |
0.255 |
|
| 2020 |
Bluethmann SM, Wang M, Wasserman E, Chen C, Zaorsky NG, Hohl RJ, McDonald AC. Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry. Cancer Medicine. PMID 32212232 DOI: 10.1002/Cam4.3003 |
0.254 |
|
| 2005 |
Schlueter AJ, Glasgow JK, Wilke WW, Marietta JR, Hohl RJ, Carter TH, Gingrich RD, Magalhaes-Silverman MD. Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant for Multiple Myeloma. Blood. 106: 5212-5212. DOI: 10.1182/Blood.V106.11.5212.5212 |
0.254 |
|
| 2006 |
Siegel DS, Krishnan A, Lonial S, Chatta G, Alsina M, Jagannath S, Richardson P, Hohl RJ, Lust JA, Bensinger W, Carrum G, Moreb J, Simic A, Barlogie B, Maziarz RT, et al. Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). Blood. 108: 3580-3580. DOI: 10.1182/Blood.V108.11.3580.3580 |
0.254 |
|
| 2018 |
Poulose J, Pu JJ, Malysz J, Bayerl M, Fanburg-Smith J, Hohl RJ, Mineishi S, Zhu J. Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: A pilot study. Journal of Clinical Oncology. 36: 7071-7071. DOI: 10.1200/Jco.2018.36.15_Suppl.7071 |
0.253 |
|
| 2013 |
Hohl RJ, Vestal RE, Holstein SA, Olson RD, Parrott K, Walsh GM. Phase I dose-escalation clinical trial with 5-imino-13-deoxydoxorubicin in cancer patients. Journal of Clinical Oncology. 31: 2575-2575. DOI: 10.1200/Jco.2013.31.15_Suppl.2575 |
0.252 |
|
| 1998 |
Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264 Journal of Clinical Oncology. 16: 1811-1819. PMID 9586895 DOI: 10.1200/Jco.1998.16.5.1811 |
0.252 |
|
| 2009 |
Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia & Lymphoma. 50: 1589-96. PMID 19863336 DOI: 10.1080/10428190903150839 |
0.252 |
|
| 2005 |
HOHL R, WIDNESS J, ROBERT S, GOLDMAN F, ALHUNITI N, VENGPEDERSON P. Change in erythropoietin pharmacokinetics in patients receiving hematopoietic stem cell transplantation Clinical Pharmacology & Therapeutics. 77: P16-P16. DOI: 10.1016/J.Clpt.2004.11.064 |
0.251 |
|
| 1999 |
Lee CK, Gingrich RD, DeMagalhaes-Silverman M, Hohl RJ, Joyce JK, Scott SD, Wen BC, Schlueter A. Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation Biology of Blood and Marrow Transplantation. 5: 15-27. PMID 10232737 DOI: 10.1053/Bbmt.1999.V5.Pm10232737 |
0.25 |
|
| 2019 |
Bodeker KL, Allen BG, Smith MC, Monga V, Sandhu S, Hohl RJ, Carlisle TL, Brown HA, Hollenbeck NJ, Vollstedt S, Greenlee JDW, Howard MA, Mapuskar KA, Seyedin SN, Caster JM, et al. First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31427282 DOI: 10.1158/1078-0432.Ccr-19-0594 |
0.249 |
|
| 2002 |
Lee CK, deMagalhaes-Silverman M, Hayashi M, Schlueter A, Strauss RG, Hohl RJ, Gingrich RD. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation Bone Marrow Transplantation. 29: 647-652. PMID 12180108 DOI: 10.1038/Sj.Bmt.1703533 |
0.247 |
|
| 2007 |
Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation Clinical Pharmacology and Therapeutics. 81: 873-879. PMID 17429351 DOI: 10.1038/Sj.Clpt.6100165 |
0.246 |
|
| 2015 |
Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature. The American Journal of Dermatopathology. PMID 25747810 DOI: 10.1097/Dad.0000000000000272 |
0.246 |
|
| 2017 |
Hohl RJ. Anticoagulants: Major Advances Without Clear Consensus. Clinical Pharmacology and Therapeutics. 100: 116-8. PMID 27393187 DOI: 10.1002/Cpt.399 |
0.246 |
|
| 2020 |
Wang M, Wasserman E, Geyer N, Carroll RM, Zhao S, Zhang L, Hohl R, Lengerich EJ, McDonald AC. Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014. Bmc Cancer. 20: 394. PMID 32375682 DOI: 10.1186/S12885-020-06902-5 |
0.243 |
|
| 2000 |
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer. 83: 588-93. PMID 10944597 DOI: 10.1054/Bjoc.2000.1316 |
0.241 |
|
| 2003 |
Venook AP, Klein CE, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 Annals of Oncology. 14: 1783-1790. PMID 14630685 DOI: 10.1093/Annonc/Mdg493 |
0.24 |
|
| 2005 |
Magalhaes-Silverman M, Carter T, Hohl R, Shamsuddin H, Gingrich R. Vanganciclovir prophylaxis for the prevention of cytomegalovirus reactivation and disease in allogeneic stem cell transplantation recipients Biology of Blood and Marrow Transplantation. 11: 87-88. DOI: 10.1016/J.Bbmt.2004.12.258 |
0.24 |
|
| 2017 |
Lee J, Blumenthal GM, Hohl RJ, Huang SM. Cancer Therapy: Shooting for the Moon. Clinical Pharmacology and Therapeutics. 101: 552-558. PMID 28418166 DOI: 10.1002/Cpt.655 |
0.237 |
|
| 2022 |
Manfredi B, Neighbors JD, Hohl RJ. Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells. Pharmacology. 1-14. PMID 35810739 DOI: 10.1159/000525299 |
0.236 |
|
| 1989 |
Hohl RJ, Schilsky RL. Nonmalignant complications of therapy for Hodgkin's disease Hematology/Oncology Clinics of North America. 3: 331-343. PMID 2663831 DOI: 10.1016/S0889-8588(18)30560-4 |
0.236 |
|
| 2019 |
Zheng H, Mineishi S, Claxton DF, Zhu J, Zhao C, Jia B, Ehmann WC, Naik S, Songdej N, Hohl RJ. Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients Blood. 134: 3939-3939. DOI: 10.1182/Blood-2019-125153 |
0.234 |
|
| 2019 |
McDonald AC, Wasserman E, Lengerich EJ, Raman JD, Geyer N, Hohl R, Wang M. Abstract 4186: Aggressive prostate cancer among men in Pennsylvania: Differences between Appalachian and non-Appalachian counties Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4186 |
0.233 |
|
| 2005 |
Magalhaes-Silverman M, Carter T, Hohl R, Shamsuddin H, Gingrich R. Antifungal prophylaxis with voriconazole in allogeneic hematopoietic stem cell transplantation recipients Biology of Blood and Marrow Transplantation. 11: 89. DOI: 10.1016/J.Bbmt.2004.12.262 |
0.231 |
|
| 2016 |
Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. PMID 27579614 DOI: 10.18632/Oncotarget.11617 |
0.23 |
|
| 2016 |
Xiu J, Reddy SK, Kesari S, McLaughlin SE, Hohl RJ, Barger G, Heimberger AB. Comparison of molecular alteration in glioblastoma tumors from old and young patients. Journal of Clinical Oncology. 34: 2056-2056. DOI: 10.1200/Jco.2016.34.15_Suppl.2056 |
0.23 |
|
| 2020 |
McDonald AC, Wasserman E, Lengerich EJ, Raman JD, Geyer NR, Hohl RJ, Wang M. Prostate Cancer Incidence and Aggressiveness in Appalachia versus Non-Appalachia Populations in Pennsylvania by Urban-Rural Regions, 2004-2014. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32277006 DOI: 10.1158/1055-9965.Epi-19-1232 |
0.227 |
|
| 2006 |
Foss F, Duvic M, Geskin L, Anderson J, Porcu P, Hohl RJ, Cooper M, Zain JM, Zic J, Hibberd P, Acosta M. Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status. Blood. 108: 2712-2712. DOI: 10.1182/Blood.V108.11.2712.2712 |
0.226 |
|
| 1997 |
Hohl RJ, Pogatchnik DM, Lewis-Tibesar K, Wiemer DF. Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids Clinical Pharmacology and Therapeutics. 61: 144. |
0.225 |
|
| 2008 |
McLennan G, Clarke L, Hohl RJ. Imaging as a biomarker for therapy response: Cancer as a prototype for the creation of research resources Clinical Pharmacology and Therapeutics. 84: 433-436. PMID 18802422 DOI: 10.1038/Clpt.2008.171 |
0.224 |
|
| 1996 |
Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clinical Cancer Research. 2: 483-491. PMID 9816194 |
0.222 |
|
| 2005 |
Xing D, Hohl R, Martins J. Lovastatin is antiarrhythmic in ischemic heart tissue by blocking triggered activity Heart Rhythm. 2: S217. DOI: 10.1016/J.Hrthm.2005.02.679 |
0.221 |
|
| 2014 |
Hohl RJ. Drug development (and academic medicine): charting the course forward Clinical Pharmacology and Therapeutics. 96: 519-522. PMID 25336261 DOI: 10.1038/Clpt.2014.171 |
0.22 |
|
| 2012 |
Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 771-6. PMID 21642514 DOI: 10.1093/Annonc/Mdr265 |
0.218 |
|
| 2010 |
Phillips PS, Verity MA, Schick BA, Vladutiu GD, Laaksonen R, Oresic M, Hohl RJ, Ciaraldi TP, Sukhatme VP, Lecker SH, Cote HCF, Powell H, Davidson W, Wolfson T. Survey of muscle characteristics after statin-induced rhabdomyolysis Clinical Lipidology. 5: 17-27. DOI: 10.2217/Clp.09.83 |
0.218 |
|
| 2008 |
Ryken T, Carlisle T, Buatti J, Kirby P, Maley J, Hohl R, Smith BJ, Greenlee J, Frees M, Rogers M. Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 13003. PMID 27951249 DOI: 10.1200/Jco.2008.26.15_Suppl.13003 |
0.216 |
|
| 2013 |
Hohl RJ. Personalized medicine: through the looking glass of functional imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4024-6. PMID 23785049 DOI: 10.1158/1078-0432.Ccr-13-1129 |
0.215 |
|
| 2012 |
Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya T, Kucaba T, Wang M, Abdulkawy H, Casavant T, Morcuende J, Buckwalter J, Hohl R, et al. Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma. 2012: 820254. PMID 22448124 DOI: 10.1155/2012/820254 |
0.215 |
|
| 2019 |
Huang X, Sterling NW, Du G, Sun D, Stetter C, Kong L, Zhu Y, Neighbors J, Lewis MM, Chen H, Hohl RJ, Mailman RB. Brain cholesterol metabolism and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30681742 DOI: 10.1002/Mds.27609 |
0.212 |
|
| 2011 |
Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science Clinical Pharmacology and Therapeutics. 90: 10-13. PMID 21691266 DOI: 10.1038/Clpt.2011.80 |
0.212 |
|
| 2007 |
Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3055-60. PMID 17634483 DOI: 10.1200/Jco.2007.11.6210 |
0.21 |
|
| 1998 |
Hohl RJ, Sherburne AR, Feeley JE, Huisman THJ, Burns CP. Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly American Journal of Hematology. 59: 181-184. PMID 9798654 DOI: 10.1002/(Sici)1096-8652(199811)59:3<181::Aid-Ajh1>3.0.Co;2-I |
0.21 |
|
| 2009 |
Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, ... Hohl RJ, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1800-5. PMID 19255312 DOI: 10.1200/Jco.2008.20.0931 |
0.205 |
|
| 2002 |
Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 15: 163-70. PMID 11849913 DOI: 10.1016/S0928-0987(01)00214-7 |
0.198 |
|
| 2003 |
Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, Fleckenstein L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clinical Pharmacology & Therapeutics. 73: P94-P94. DOI: 10.1016/S0009-9236(03)90702-8 |
0.198 |
|
| 2006 |
Magalhaes-Silverma M, Leopold C, Cater T, Hohl R, Gingrich R. Pre-Transplant Smoking and Transplant-Related Mortality from Pulmonary Causes in Recipients of Allogeneic Stem Cell Transplants. Blood. 108: 5342-5342. DOI: 10.1182/Blood.V108.11.5342.5342 |
0.193 |
|
| 2007 |
Hohl RJ. Clinical pharmacology: Bridging discovery and practice Clinical Pharmacology and Therapeutics. 81: 783-785. PMID 17505487 DOI: 10.1038/Sj.Clpt.6100225 |
0.192 |
|
| 2015 |
Hohl RJ. Oncology trial design: More accurately and efficiently advancing the field Clinical Pharmacology and Therapeutics. 97: 430-432. PMID 25684240 DOI: 10.1002/Cpt.94 |
0.188 |
|
| 2009 |
Holstein SA, Hohl RJ. Vascular medicine: A look forward Clinical Pharmacology and Therapeutics. 86: 117-119. PMID 19621001 DOI: 10.1038/Clpt.2009.125 |
0.18 |
|
| 1996 |
Peters C, Miller J, Abel SL, McMillan SK, Getchell JP, Giller RH, Hohl RJ, De Alarcon PA. Iowa newborn hemoglobinopathy screening and comprehensive care: A model for rural states [1] Journal of Pediatric Hematology/Oncology. 18: 416-418. PMID 8888756 DOI: 10.1097/00043426-199611000-00018 |
0.178 |
|
| 2021 |
Weissenrieder JS, Reed JL, Moldovan GL, Johnson MT, Trebak M, Neighbors JD, Mailman RB, Hohl RJ. Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D receptor-dependent, manner. Pharmacology Research & Perspectives. 9: e00689. PMID 34003586 DOI: 10.1002/prp2.689 |
0.169 |
|
| 1991 |
Hohl RJ, Kennedy EJ, Frischer H. Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs. The Journal of Laboratory and Clinical Medicine. 117: 325-31. PMID 1901343 |
0.149 |
|
| 2001 |
Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, Mcguire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway Journal of Pharmacology and Experimental Therapeutics. 298: 820-824. PMID 11454947 |
0.132 |
|
| 2004 |
Veng-Pedersen P, Chapel S, Al-Huniti NH, Schimdt RL, Sedars EM, Hohl RJ, Widness JA. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phylebotomy-induced anemia and bone marrow ablation Biopharmaceutics and Drug Disposition. 25: 149-156. PMID 15108217 DOI: 10.1002/bdd.395 |
0.128 |
|
| 2022 |
Zhao C, Bartock M, Jia B, Shah N, Claxton DF, Wirk B, Rakszawski KL, Nickolich MS, Naik SG, Rybka WB, Ehmann WCC, Hohl RJ, Valentin J, Bernas-Peterson M, Gerber EM, et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. Journal of Hematology & Oncology. 15: 64. PMID 35590334 DOI: 10.1186/s13045-022-01287-3 |
0.125 |
|
| 1999 |
Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473 Clinical Cancer Research. 5: 3942-3947. PMID 10632323 |
0.122 |
|
| 2022 |
Shah N, Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, Rybka W, Ehmann C, Silar B, Vajdic C, Mierski J, Zhou S, Shike H, Greiner R, ... ... Hohl R, et al. Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide. Leukemia Research. 123: 106969. PMID 36306723 DOI: 10.1016/j.leukres.2022.106969 |
0.106 |
|
| 2000 |
Choon-Kee L, De Magalhaes-Silverman M, Hohl RJ, Hayashi M, Schlueter A, Gingrich RD. A phase-I, dose escalation study for salvage chemotherapy for patients with refractory lymphoma, prior to myeloablative therapy with stem cell transplantation Blood. 96. |
0.104 |
|
| 2003 |
Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft Bone Marrow Transplantation. 31: 121-128. PMID 12621494 DOI: 10.1038/sj.bmt.1703803 |
0.102 |
|
| 2024 |
Guare EG, Hale CM, Sivik J, Lehman E, Inoue Y, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Claxton D, Rybka W, Hohl R, Mineishi S, Minagawa K, et al. The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma. Transplant Infectious Disease : An Official Journal of the Transplantation Society. e14241. PMID 38269469 DOI: 10.1111/tid.14241 |
0.097 |
|
| 2022 |
Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, Rybka W, Ehmann C, Silar B, Vajdic C, Shah N, Tuanquin L, Greiner R, Brown V, Hohl R, et al. Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis. Annals of Hematology. PMID 36527460 DOI: 10.1007/s00277-022-05077-2 |
0.094 |
|
| 2015 |
Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors Investigational New Drugs. DOI: 10.1007/s10637-015-0220-z |
0.09 |
|
| 2020 |
Zheng H, Mineishi S, Claxton D, Zhu J, Zhao C, Jia B, Ehmann WC, Rybka WB, Naik S, Songdej N, Drabick JJ, Hohl RJ. A Phase I Clinical Trial of Avelumab in Combination with Decitabine as First Line Treatment of Unfit patients with AML. American Journal of Hematology. PMID 33146922 DOI: 10.1002/ajh.26043 |
0.082 |
|
| 1995 |
Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation Bone Marrow Transplantation. 16: 175-182. PMID 7581119 |
0.08 |
|
| 1996 |
Lee CK, Harman GS, Hohl RJ, Gingrich RD. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplantation. 18: 573-7. PMID 8879620 |
0.075 |
|
| 2000 |
Lee CK, Hohl RJ, Masaki H, Schlueter A, Field E, Gingrich RD. Allogeneic hematopoietic stem cell (hsct) in patients with advanced hematological diseases using a non-myeloablative conditioning regimen Blood. 96. |
0.073 |
|
| 2004 |
Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 101: 370-8. PMID 15241836 DOI: 10.1002/cncr.20362 |
0.068 |
|
| 2005 |
Xing D, Hohl RJ, Martins JB. 71 LOVASTATIN IS ANTIARRHYTHMIC IN ISCHEMIC HEART TISSUE BY BLOCKING TRIGGERED ACTIVITY Journal of Investigative Medicine. 53: S368.5-S368. DOI: 10.2310/6650.2005.00206.70 |
0.067 |
|
| 2000 |
Lee CK, Hohl RJ, Schlueter A, Hayashi M, Field E, Gingrich RD. Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders Blood. 96. |
0.03 |
|
| 1980 |
Beiderbeck R, Hohl R. Die Wirkung zeitlich begrenzter Phytohormongaben auf isolierte Mesophyllzellen von Calystegia sepium L. Biochemie Und Physiologie Der Pflanzen. 175: 45-49. DOI: 10.1016/S0015-3796(80)80089-8 |
0.01 |
|
| Hide low-probability matches. |